Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 3
Submit an article Journal homepage
1,328
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study

David Quallsa Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-5297-9685View further author information
ORCID Icon,
Ariela Noyb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-3001-4898View further author information
ORCID Icon,
David Strausb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-8364-6816View further author information
ORCID Icon,
Matthew Matasarb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-4581-3721View further author information
ORCID Icon,
Craig Moskowitzb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;d Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USAORCID Iconhttps://orcid.org/0000-0002-9189-3152View further author information
ORCID Icon,
Venkatraman Seshane Department of Epidemiology and Biostatistics, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Ahmet Doganf Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-6576-5256View further author information
ORCID Icon,
Gilles Sallesb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-9541-8666View further author information
ORCID Icon,
Anas Younesb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-0001-4133View further author information
ORCID Icon,
Andrew D. Zelenetzb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-1403-6883View further author information
ORCID Icon &
Connie Lee Batlevib Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9036-9463View further author information
ORCID Icon show all
Pages 738-741 | Received 07 Nov 2022, Accepted 24 Dec 2022, Published online: 15 Jan 2023

References

  • Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471(7337):189–195.
  • Batlevi CL, Crump M, Andreadis C, et al. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. Br J Haematol. 2017;178(3):434–441.
  • Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008;19(5):964–969.
  • Ogura M, Ando K, Suzuki T, et al. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2014;165(6):768–776.
  • Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(9):1198–1203.
  • Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016;128(2):185–194.
  • Ribrag V, Kim WS, Bouabdallah R, et al. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica. 2017;102(5):903–909.
  • Kalkhoven E. CBP and p300: HATs for different occasions. Biochem Pharmacol. 2004;68(6):1145–1155.
  • Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000;14(13):1553–1577.
  • Ogryzko VV, Schiltz RL, Russanova V, et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87(5):953–959.
  • Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 1996;384(6610):641–643.
  • Lill NL, Grossman SR, Ginsberg D, et al. Binding and modulation of p53 by p300/CBP coactivators. Nature. 1997;387(6635):823–827.
  • Gu W, Shi XL, Roeder RG. Synergistic activation of transcription by CBP and p53. Nature. 1997;387(6635):819–823.
  • Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet. 2002;32(4):606–613.
  • Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004;432(7017):635–639.
  • Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251–264.
  • Ptashkin RN, Ewalt MD, Jayakumaran G, et al. Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing. medRxiv; 2022.
  • Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433–1442.
  • Gui L, Cheng Y, Wang H, et al. Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma. J Clin Oncol. 2022;40(16_Suppl.):7513.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.